Theravance Biopharma (TBPH) Phase 2b Dose-Finding Induction Study of Izencitinib Did Not Meet Primary Endpoint
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Theravance Biopharma (TBPH) PT Lowered to $18 at Needham & Company
August 24, 2021 6:24 AM EDTNeedham & Company analyst Joseph Stringer lowered the price target on Theravance Biopharma (NASDAQ: TBPH) to $18.00 (from $32.00) while maintaining a Buy rating.
The analyst commented, "TBPH announced yesterday the izencitinib Ph2b RHEA trial in Ulcerative Colitis (UC) failed to demonstrate efficacy vs... More
Theravance Biopharma (TBPH) falls 21% as trading resumes after a trial missed the primary endpoint
August 23, 2021 4:37 PM EDTTheravance Biopharma (NASDAQ: TBPH) falls 21% as trading resumes after a trial missed the primary endpoint.
... MoreTheravance Biopharma (TBPH) to resume trading at 4:35PM ET after a trial did not meet the primary endpoint
August 23, 2021 4:10 PM EDTTheravance Biopharma (NASDAQ: TBPH) to resume trading at 4:35PM ET after a trial did not meet the primary endpoint.
... More